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Alzheimer’s disease (AD) is a most common neurodegenerative disorder, which associates with impaired cognition. Gut 
microbiota can modulate host brain function and behavior via microbiota-gut-brain axis, including cognitive behavior. 
Germ-free animals, antibiotics, probiotics intervention and diet can induce alterations of gut microbiota and gut physiology and 
also host cognitive behavior, increasing or decreasing risks of AD. The increased permeability of intestine and blood-brain 
barrier induced by gut microbiota disturbance will increase the incidence of neurodegeneration disorders. Gut microbial 
metabolites and their effects on host neurochemical changes may increase or decrease the risk of AD. Pathogenic microbes 
infection will also increase the risk of AD, and meanwhile, the onset of AD support the “hygiene hypothesis”. All the results 
suggest that AD may begin in the gut, and is closely related to the imbalance of gut microbiota. Modulation of gut microbiota 
through personalized diet or beneficial microbiota intervention will probably become a new treatment for AD. 
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Alzheimer’s disease (AD), commonly known as senile 
dementia or cognitive disorder, is a common central 
nervous system degenerative disease in the elderly. AD is 
one of the most common form of dementia, accounting for 
60%–80% of all dementia (Alzheimer’s Association, 2015). 
It is estimated that about 36 million people lived with 
dementia worldwide in 2010 and the numbers were 
expected to double every 20 years. The numbers will reach 
to 66 million in 2030 and 115 million in 2050 (Prince et al., 
2013). With the acceleration of population aging in the 
world, the incidence of AD rises year by year, which 
seriously damage the old people’s physical and mental 
health and quality of life, causing severe pain to the patients 
and bringing heavy burden to family and society. China’s 
population aging also reached an unprecedented level. The 
2010 nationwide census data showed that the elderly 
population accounted for more than 10% of the population 
in our country. To speculate according to the current 
incidence, China will have 8–12 million AD patients by 
2050. The high incidence and morbidity of AD have 
become a major problem affecting human health, which 
aroused widespread concern in government and medical 
community and become a hotspot and difficulty in the field 
of neuroscience research.  
The neuropathological hallmarks of AD include 
extracellular -amyloid (A) senile plaques (SP) and 
intracellular neurofibrillary tangles (NFT) (Reitz et al., 
2011). At present, it is generally considered that the 
interaction between genetic and environmental factors takes 
part in AD pathogenesis. Through genome-wide association 
studies in AD patients, some genomic regions associated 
with AD were discovered and some susceptibility genes of 
AD had been identified, mainly involving in the immune 
reaction, inflammation, cell migration and lipids transport 
pathways (Lambert et al., 2013). Apolipoprotein E (ApoE) 
is one of the most common susceptibility genes, with three 
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allele polymorphism (2, 3 and 4), in which 2 is a 
protective allele, 3 is a neutral allele and 4 is a high-risk 
allele. The 4 influences onset age of AD in a 
dose-dependent manner (Reitz et al., 2011). The genes are 
inherited from parents and cannot be changed, but there are 
also some non-genetic factors affecting the risk of AD, such 
as occupational exposure to hazardous materials, physical 
disease status and lifestyle factors. The non-genetic 
environmental factors are thought to be associated with 
genetic susceptibility genes to increase AD pathogenesis. 
Although aging, family history and susceptibility genes 
have been considered to be the most important factors, the 
rapid increasing of AD do not conform to Hardy-Weinberg 
equilibrium. We therefore, think that environmental factors 
are more important than genetic factors in AD. Recently, 
more and more studies suggested that human symbiotic 
microbes were very important environmental factors 
influencing host health. About 95% of the symbiotic 
microbes are located in the gut, which play a major role in 
human nutrition, digestion, neurotrophy, inflammation, 
growth, immunity and protecting against pathogen 
infections (Hooper and Gordon, 2001). The gut microbiota 
also regulates brain function and behavior through 
microbiota-gut-brain axis. Many diseases have been found 
to be related with the number and composition of gut 
microbiota, including obesity (Ley et al., 2006), diabetes 
(Qin et al., 2012), hypertension (Yang et al., 2015), liver 
cirrhosis (Qin et al., 2014), autism (Finegold et al., 2010), 
depression (Naseribafrouei et al., 2014), Parkinson’s disease 
(Scheperjans et al., 2015), and so on. However, the research 
on AD and gut microbiota is just beginning. Based on the 
existing researches, such as epidemiological investigation of 
AD, effect of gut microbiota on brain function and behavior 
as well as the effect of gut microbiota in pathogenesis of 
autism, depression, and Parkinson’s disease, we have reason 
to speculate that AD begin in the gut, and relate to the 
imbalance of gut microbiota. 
GUT MICROBIOTA INFLUENCE BRAIN 
DEVELOPMENT AND BEHAVIOR 
Gut microbiota 
After completion of the Human Genome Project, only about 
26,600 protein-coding genes were discovered, which were 
far less than that researchers predicted before the project. 
Scientists still could not conclude most of the phenomenon 
on growth, development, disease and death of human. The 
number was even far less than the rice genome, which has 
about 46,000 genes. This has also become a human    
genome-complexity conundrum puzzling the scientists 
around the world. Until recent years, researchers started to 
concern the genome of human symbiotic microbes (Qin et 
al., 2010). The human body is the natural habitat of 
symbiotic microbes, including archaea, bacteria, fungi, 
viruses, etc. It is estimated that there are about 1,000 
species, 1014 bacteria only in the gut. The bacterial density 
is about 1011–1012 per mL in the gut, which is the highest 
density in any recorded microbial ecosystem. The 
compositions of gut microbiota are different between 
individuals. Different bacterial structure also determines the 
difference of human biochemistry, genetic individuality and 
resistance to diseases (Aziz et al., 2013). Bacteroidetes and 
Firmicutes are two dominant bacterial phylum in the gut, 
with Proteobacteria, Verrucomicrobiota, Fusobacteria, 
Cyanobacteria, Actinbacteria, Spirochetes, and so on as the 
remainder (Backhed et al., 2005). The gut microbiota 
encode about 4,000,000 genes, making the human genetic 
complexity closer to 4,026,600 genes when plus the 26,600 
host genes, which far more than rice and other species 
(Human Microbiome Project Consortium, 2012; Venter et 
al., 2001). This not only explained the human 
genome-complexity conundrum, but also reflected the 
importance of gut microbiota on human normal 
physiological function. People usually thought the intestinal 
contents are just no use to human body, now we begin to 
realize that the microorganisms and their metabolic 
products are important to human health. Gut microbiota 
play an important role in maintaining host health through 
defensing against pathogen, metabolism of dietary nutrition, 
affecting food absorption, and so on (Cho and Blaser, 
2012). There is also a complex nervous system in human 
intestine and more and more clinical studies and scientific 
research evidences suggested a communication between gut 
microbiota and central nervous system (CNS) (Bravo et al., 
2012).  
Gut microbiota and brain development 
Gut-brain axis is a complex bidirectional communication 
network between the gut and the brain (Cryan and Dinan, 
2012). Recent studies suggested that gut microbiota 
participated in the functions of gut-brain axis and played a 
major role in signaling communication between gut and 
brain, so the gut-brain axis was extended to 
microbiota-gut-brain axis, which modulates immune, gut 
and CNS functions (Cryan and O’Mahony, 2011). In 
healthy individuals, gut microbiota is relatively stable to 
form a host-bacterial mutualism. The disruption of 
host-bacterial mutualism would increase the dysfunction of 
brain, digestive system and metabolism (Cryan and 
O’Mahony, 2011). For example, bidirectional signaling 
communication between gut microbiota and CNS could 
influence host stress response, pain perception, 
neurochemical and gut-brain axis abnormalities (Collins et 
al., 2012; Cryan and Dinan, 2012; Foster, 2013). Germ-free 
(GF) animal studies have shown that gut microbiota can 
affect animal’s behavior and be able to change the brain 
physiology and neural biochemical characteristics (Diaz 
Heijtz et al., 2011). Hypothalamic-pituitary-adrenal axis 
(HPA) is important part of neuroendocrine system, 
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participates in regulating stress responsiveness and many 
physiological activities, such as digestion, immunity, 
behavior, and so on. The development of HPA in GF mice 
is abnormal, leading to altered response to stress and 
reduced expression of brain-derived neurotrophic factor 
(BDNF) (Sudo et al., 2004). Colonization of GF mice with 
normal gut microbiota from conventionally raised mice or 
specific probiotic Bifidobacterium infantis could reverse 
these abnormalities (Sudo et al., 2004). These results 
suggested that the activity of HPA was regulated by gut 
microbiota and also suggested the important role of gut 
microbiota on nervous system development. 
The human body is almost sterile at birth, but in a very 
short time after birth, bacteria will be rapid colonized in the 
gut and continues to develop and mature during childhood 
and adolescence. Therefore, the colonization and 
development of gut microbiota in early life can determine 
the physical and mental health in the later life. Similar to the 
development and maturation of gut microbiota, childhood 
and adolescence are also critical periods for brain 
development. Hence, disruption of host-microbiota 
mutualism in these periods would change the gut-brain axis 
signals and affect the health in the whole life, increasing the 
risk of neurodevelopment disorders. The instability and 
immaturity of gut microbiota during these periods also 
make the individuals be more easily affected by 
environmental factors, such as antibiotics use, stress, poor 
diet, infection, and so on will lead to dysbiosis of gut 
microbiota and have a harmful impact on physical and 
mental health, resulting in brain disorders in later life (Borre 
et al., 2014). To adulthood, gut microbiota tends to be more 
mature and stable and the brain development is also close to 
maturity, but synaptic pruning and myelination still 
continue to occur (Sowell et al., 2003). Thus, the alteration 
of gut microbiota in this period may also affect the brain 
function and behavior. Maintaining a health gut microbiota 
during the colonization, development and maturation stage 
is important to prevent aging associated brain disorders. 
Aging period is not a critical stage for neurodevelopment, 
but the body will display chronic progressive 
proinflammatory response during aging, knowing as 
inflammaging (Franceschi, 2007), which will gradually 
destroy the balance of gut microbiota and seriously affect 
the composition of gut microbiota (Guigoz et al., 2008; 
O’Toole and Claesson, 2010), resulting in gradually decline 
of microbiota diversity and stability (Biagi et al., 2010; 
Claesson et al., 2011). Gut microbiota composition of aged 
people was usually affected by living environment, dietary 
habit and the health status of individuals (Claesson et al., 
2012). In addition, drugs uses, degeneration of digestive and 
gastrointestinal motility, malabsorption of nutrients and 
impaired immunity also influence gut microbiota 
composition (Biagi et al., 2013). The decreased diversity of 
gut microbiota in old people is usually accompanied by 
reduced brain weight and cognitive functions. A study 
found that brain weight begins to decline from about 45–50 
years age and reaches to the lowest after 86 years age, by 
which time the mean brain weight decreases about 11% 
comparing to maximum brain weight (Dekaban, 1978). The 
aging associated brain morphology changes usually occur 
with impaired immune system, increased oxidative stress 
and accumulation of brain amyloid plaques, which are 
generally shown in a variety of aging associated memory 
disorders, such as AD. Claesson et al. focused on the gut 
microbiota characteristics of the elderly and found that 
nutrition is very important (Claesson et al., 2012). This also 
suggested that modulating gut microbiota and restoring its 
diversity in the elderly through diet and nutrition 
intervention might improve the elderly’s physical and 
mental health.  
Host gut microbiota also constantly control maturation 
and function of microglia in the CNS. GF mice displayed 
global defects in microglia with altered cell number and 
immature development, which directly lead to impaired 
immune responses and then result in pathogenesis of 
neurological diseases including AD (Erny et al., 2015). 
Therefore, maintaining a healthy gut microbiota is very 
important for maintaining normal brain development and 
function.  
DIRECT EVIDENCE OF GUT MICROBIOTA 
AFFECT AD 
Gut microbiota and cognitive behavior 
In recent years, researches on gut microbiota attracted more 
and more attention. Gut microbiota plays an important role 
in maintaining host normal physiology and functions. The 
changes of gut microbiota can also lead to changes of brain 
function and thus affect the host behavior (Sampson and 
Mazmanian, 2015). Recent studies also suggested a 
significant correlation between the changes of gut 
microbiota and cognitive behavior. Modulation of gut 
microbiota, by using germ-free animals, probiotics or 
antibiotics intervention and fecal microbiota transplantation 
(FMT), can modulate host cognitive behavior. Compared 
with specific pathogen free (SPF) mice, GF mice showed 
the defects in spatial memory and working memory (Gareau 
et al., 2011). Antibiotics will seriously disrupt the gut 
microbiota. Wang et al. treated weaning Sprague-Dawley 
(SD) rats with ampicillin for 1 month, resulting in 
disruption of gut microbiota, elevation of serum 
corticosterone, increased anxiety-like behavior and 
impairment of spatial memory. Lactobacillus fermentum 
NS9 administration restored the physiological and 
psychological abnormalities induced by ampicillin (Wang et 
al., 2015). Citrobacter rodentium is a gram negative 
pathogenic bacterium, which could cause temporary 
enteritis in mice and change the composition of gut 
microbiota. C. rodentium infection is not enough to change 
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the memory and cognition in mice, but exposure to a 
psychological stress at the same time leads to reduced 
non-spatial recognition memory and working memory. 
Using probiotics intervention 1 week before infection can 
not only effectively restore the infection induced gut 
microbiota imbalance, but also prevent stress induced 
cognitive behavior changes (Gareau et al., 2011). Liang et 
al. found that probiotic Lactobacillus helveticus NS8 could 
significantly improve cognitive function disorders caused 
by chronic restraint stress in rats (Liang et al., 2015). Luo et 
al. built a hyperammonemia rat model by intraperitoneal 
injection of ammonium acetate for 4 weeks and found that 
the learning and memory ability of rat were significantly 
decreased in Morris water maze test. Administration of 
Lactobacillus helveticus NS8 could significantly improve 
the cognitive behavioral abnormalities (Luo et al., 2014). 
Other studies have shown that Lactobacillus helveticus 
fermented milk could significantly improves the learning 
and memory impairment induced by scopolamine in mice 
(Ohsawa et al., 2015). Bifidobacterium longum 1714 could 
obviously increase the learning and memory ability 
displayed in object recognition, Barnes maze and fear 
conditioning test (Savignac et al., 2015). In a human study 
of healthy women volunteers, consumption of fermented 
milk product with probiotics changed the intrinsic activity 
of resting brain, displaying affected activity of brain regions 
that control central processing of emotion and sensation 
assessed by neuroimaging using fMRI (Tillisch et al., 
2013). Similarly, taking a probiotic formulation consisting 
of Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175 can obviously improve the cognitive 
behavior efforts response to external stimuli in healthy 
human subjects (Messaoudi et al., 2011). 
Obesity may reduce brain function and increase the risk 
of AD. Now, researchers think that this is not necessarily 
caused by obesity itself, other factors associated with 
obesity might play an important role, such as gut 
microbiota. Bruce-Keller et al. fed C57BL/6 mice with 
regular chow diet or high fat diet firstly for 10 weeks, high 
fat fed mice increased more weight than regular chow fed 
mice. Then the cecal plus colonic microbiota were 
harvested from the high fat or regular chow fed mice, and 
transplanted to mice with normal weight and microbiota 
depletion by antibiotics. Results showed that the mice 
transplanted with high fat fed microbiota reflected selective 
disruptions in exploratory, cognitive and stereotypical 
behavior and accompanied with increase intestinal 
permeability, systemic inflammation and brain 
inflammation (Bruce-Keller et al., 2015). These data 
suggested that high fat diet related behavior changes were 
likely to be caused by diet induce changes of gut 
microbiota. Gut microbiota may participate in regulating 
cognitive behavior.  
Impaired cognitive behavior is one of the pathological 
characteristics of AD. The role of gut microbiota in 
cognitive behavior also suggest the potential role of gut 
microbiota in the development of AD. 
Diet, gut microbiota and AD 
The role of diet in disease development and prevention is 
always under the spotlight. Previous studies think that 
widespread use of gluten and sugar in food and lack of 
healthy fat intake would cause the systemic inflammation, 
eventually attack the CNS functions and affect the brain 
health. New evidences showed that the influence of diet on 
brain health was not because of the diet induced 
inflammatory response, but the disruption of diet on gut 
microbiota. The scientists from European Molecular 
Biology Laboratory (EMBL) and the MetaHIT Consortium 
analyzed the gut microbiota of individuals from different 
countries and regions and divided the gut microbiota into 
three predominant enterotypes, respectively dominated by 
Bacteroides, Prevotella and Ruminococcus genus 
(Arumugam et al., 2011). Bacteroides enterotype mainly 
contains species good at ferment carbohydrates and protein. 
Prevotella enterotype mainly comprises species able to 
degrade plant polysaccharides and mucin glycoproteins 
present in the mucosal layer of the gut and interacts with 
immune system. Ruminococcus enterotype is enriched in 
species which is able to degrade mucins and helps cells to 
uptake sugars (Arumugam et al., 2011). The enterotype 
appears independent of genetic background, nationality, 
sex, age and body mass index and is associated with 
long-term dietary patterns (Wu et al., 2011). Bacteroides 
enterotype is strongly associated with excessive intake of 
protein and animal fat and Prevotella enterotype is strongly 
associated with carbohydrates (Wu et al., 2011). 
Diet is usually considered to be closely associated with 
the occurrence of AD. Omega 3 polyunsaturated fatty acids 
(-3 PUFAs) are vital for neuronal and brain functions 
(Yehuda et al., 2005). The main -3 PUFAs include 
docosahexaenoic acid (DHA, 22:6) and eicosapentaenoic 
acid (EPA, 20:5). Body low levels of -3 PUFAs may be 
associated with neurodegenerative diseases, including AD. 
A study found that the serum DHA levels of AD patients 
were significantly decreased when compared with healthy 
controls (Tully et al., 2003). High intake of -3 PUFAs 
from diet can lower the risk of AD and slow age-related 
cognitive decline (Morris et al., 2003; Solfrizzi et al., 2006). 
DHA and EPA are mainly obtained from deep-sea fish, 
which is the major dietary sources of -3 PUFAs of human. 
Many surveys found that increase the fish consumption can 
significantly reduce the risk of AD (Barberger-Gateau et al., 
2002; Morris et al., 2003). Intestine is the main place to 
absorb fatty acids and -3 PUFAs absorption in intestine is 
limited by a variety of conditions, including the 
composition of fatty acids in diet, the body itself and 
existing form of fatty acids. Solakivi et al. analyzed the 
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contents and types of PUFAs in serum of 32 patients with 
irritable bowed syndrome (IBS) and 59 healthy controls and 
found that the serum DHA content of IBS patients was 
significantly decreased (Solakivi et al., 2011). These 
suggested that the absorption capacity of DHA in intestine 
of IBS patients was changed. Dietary fatty acids is one of 
the main carbon sources of gut microbiota. The gut 
microbiota can metabolite the dietary fatty acids again and 
change the composition of fatty acids in the gut and 
eventually change the body composition of fatty acids. Gut 
microbiota may also participate in the intestinal absorption 
of -3 PUFAs to a certain extent. We observed in our 
laboratory that adding probiotics to diet in pigs breeding 
could change the gut microbiota composition and DHA 
content in pork also significantly elevated (unpublished 
data). At the same time, the dietary fatty acids can also 
directly or indirectly modulate the composition of gut 
microbiota and influence the host immune system. The 
composition of gut microbiota significantly changed in mice 
fed with -3 PUFAs enriched diet (Liu et al., 2012; Yu et 
al., 2014). So, on one hand, dietary -3 PUFAs may 
influence brain functions by changing the composition of 
gut microbiota. On the other hand, healthy gut and gut 
microbiota may help promoting dietary -3 PUFAs 
absorption and reduce the risk of AD; conversely, 
dysfunctional gut and gut microbiota may reduce the 
absorption of -3 PUFAs and thereby increase the risk of 
AD. 
Eskelinen et al. followed 1,409 Finland individuals aged 
65 to 79 years for 21 years and found that people who daily 
drank three to five cups of coffee at midlife showed an 
unbelievable 65% decreased risk of AD in comparison to 
people who did not drink or drank less than two cups per 
day (Eskelinen et al., 2009). Previous studies focus on the 
protective roles of coffee on the brain because coffee is rich 
in antioxidant polyphenols which can reduce oxidative 
stress induced brain injuries and lower the risk of AD. 
Destroyed redox balance and excessive accumulation of 
reactive oxygen species (ROS) induced oxidative damage 
on the body directly involved in the pathological process of 
neurodegenerative diseases including AD (Butterfield et al., 
2006). Dietary intake of some other antioxidant nutrients, 
such as vitamin C, vitamin E, flavonoids, is also considered 
to be related to decreased risk of AD (Masaki et al., 2000; 
Morris et al., 2002; Zandi et al., 2004). The latest research 
demonstrated that the effect of coffee may occur at the level 
of the gut microbiota (Jaquet et al., 2009). Firstly, gut 
microbiota can easily digest the fiber in coffee beans and 
harvest its energy to help their own growth. Simultaneously, 
they can reduce the ratio of Firmicutes to Bacteroidetes 
bacteria and this alteration in Firmicutes to Bacteroidetes 
ratio is associated with reduced inflammation (Cowan et al., 
2014). Secondly, the capacity of body to utilize coffee 
polyphenols is also influenced by gut microbiota in a large 
extent. After consumption, polyphenols need to be degrade 
by gut microbiota into small molecules that are easily 
absorbed by human body. Therefore, in order to sufficiently 
obtain the health benefits and increase the bioavailability 
and activity of polyphenols, you need a healthy gut 
microbiota (Moco et al., 2012). The protective role of other 
antioxidants and nutrients may also depend on the balance 
of gut microbiota to some extent. Healthy gut microbiota 
may increase their biological activity and utilization and 
thus maximum exert their brain protective roles and reduce 
the risk of AD.  
Some other studies took into account the influence of 
different diet types and food combination on AD. Dietary 
intake of fruits and vegetables daily can lower the risk of 
AD because of their rich in antioxidants and vitamins 
(Hughes et al., 2010). Dietary consumption of more nuts, 
fishes and vegetable oils can also reduce the incidence of 
AD because they can provide large amounts of -3 PUFAs 
and antioxidants (Barberger-Gateau et al., 2007; Gu et al., 
2010). Western diet is characteristic with high fat and sugar. 
High fat diet can lead to cognitive impairment and 
hippocampus-dependent memory disorder and increase the 
incidence of AD. The incidence of AD was higher in 
countries with high fat or calories intake in diet and lower in 
low fat intake countries. Epidemiological survey shows that 
consumption of too much saturated fat is a high risk factor 
of AD (Eskelinen et al., 2008; Laitinen et al., 2006). High 
fat diet could induce CNS A accumulation and memory 
impairment in mice (Knight et al., 2014; Refolo et al., 
2001). More and more evidences suggest that low calorie 
diet can delay the progress of brain aging (Martin et al., 
2006). Animal experiments showed that caloric restriction 
in diet can prevent the accumulation of A and slow the 
progress of AD (Patel et al., 2005). Caloric restriction can 
also ameliorate the aging-associated cognitive deficits and 
reduce the risk of AD (Fontan-Lozano et al., 2007). Witte et 
al. found that caloric restriction about 30% for 3 months 
improved memory in elderly humans (Witte et al., 2009). 
High fat diet induced changes of gut microbiota can lead to 
increased intestinal permeability and lipopolysaccharide 
(LPS) absorption and consequently endotoxemia increases 
and triggers systemic inflammation and disease 
pathogenesis (Cani et al., 2008). Caloric restriction can 
promote host health by optimizing the gut microbiota 
composition, including the increase of bacteria positively 
related with health, such as lactobacillus, and decrease of 
bacteria negatively associated with health (Zhang et al., 
2013).  
Mediterranean diet is considered to be one of the 
healthiest diets in the world, which is characterized by 
abundant plant food such as fruits, vegetables, other forms 
of cereals, beans and nuts, olive oil as the major source of 
fat, daily intake of moderate dairy products, low to 
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moderate amounts of fish, poultry and eggs, daily moderate 
consumption of wine during meals (Willett et al., 1995). 
Epidemiological investigations found that AD and mild 
cognitive impairment (MCI) were more prevalent in people 
with low adherence to the Mediterranean diet (Gardener et 
al., 2012). Higher adherence to the Mediterranean diet is 
associated with a reduction in the risk of AD (Scarmeas et 
al., 2006). Marlow et al. showed that the Mediterranean diet 
appeared to benefit the health of Crohn’s disease patients, 
reflected by a trend for reduced inflammation biomarkers 
and normalization of the gut microbiota with increasing 
Bacteroidetes and Clostridium and decreasing 
Proteobacteria and Bacillaceae (Marlow et al., 2013). This 
also suggests that the Mediterranean diet may play 
important roles in disease control including AD through 
balancing the gut microbiota (Del Chierico et al., 2014). 
The health and diversity of gut microbiota are directly 
dependent on the food we consumed. All of the above 
studies suggest that gut microbiota plays an important role 
in diet induced increase or decrease of AD risks. However, 
the detailed mechanisms underlying the effect of gut 
microbiota in disease control especially AD remain to be 
further studied.   
Leaky gut, leaky brain and AD 
The gastrointestinal tract, from the esophagus to the anus, is 
lined with a single layer of epithelial cells, which form the 
intestinal mucosal barrier to protect the body from infection 
of pathogenic microorganisms and prevent the harmful 
particles, chemicals, bacteria and other health-threatening 
organisms to enter the blood circulation. These play 
important roles in protecting host health (Turner, 2009). The 
connection between cells called tight junction. When the 
occurrence of problems in the competency of the tight 
junctions, it will lead to increased intestinal permeability, 
which is so-called leaky gut. Disruption of intestinal barrier 
functions will cause leaky gut accompanied with increased 
inflammatory levels, and then result in the occurrence of 
diseases (Kelly et al., 2015; Turner, 2009). 
The integrity of blood-brain barrier (BBB) is vital for the 
brain development and function. In the past, people usually 
thought that the BBB was impermeable to prevent any 
possible harmful substances from entering the brain. Recent 
studies found that a lot of substances can threaten the 
integrity of the BBB, making all kinds of molecules, 
including protein, viruses and even bacteria, to enter the 
brain and threaten the brain health (Welling et al., 2015). 
Intestinal environment changes can gradually destroy the 
ability of brain to protect it from toxic substances. Leaky 
gut induced inflammation will eventually lead to leaky 
brain, which is the increased permeability of BBB.  
The destruction of the balance of gut microbiota is 
directly related to the leaky gut (Jakobsson et al., 2015). 
Stress, pathogen infection, antibiotics uses can destroy the 
gut microbiota and lead to increased intestinal permeability. 
Gut microbiota is also important for the development and 
the integrity of BBB. GF mice displayed increased 
permeability of BBB compared to SPF mice with a normal 
gut microbiota. Reconstruction of the gut microbiota in GF 
mice decreased BBB permeability and up-regulated the 
expression of tight junction proteins (Braniste et al., 2014).  
Lipopolysaccharide (LPS) is a combination of lipid and 
sugar and is a major component of the cell wall of 
gram-negative bacteria. There are about 50%–70% gram- 
negative bacteria in the normal gut microbiota. LPS, also 
called endotoxin, will induce a serious body inflammatory 
response if entering the bloodstream. In healthy condition, 
the LPS is blocked from the bloodstream by the tight 
junctions that exist between the intestinal epithelial cells. 
When the tight junctions are compromised and become 
increased permeability, LPS will finds its way into the 
bloodstream and cause inflammation. So the levels of LPS 
in the blood represent not only inflammation but also leaky 
gut. Studies found that the plasma levels of LPS in patients 
with AD were three times higher than healthy controls 
(Zhang et al., 2009). LPS is usually used to create 
inflammation in laboratory animals. Intraperitoneal 
injections of LPS to mice could cause prolonged elevation 
in hippocampal A and cognitive deficits (Kahn et al., 
2012). The hippocampus is the memory center of brain and 
A is a key protein of AD. In AD patients, the increased 
blood-to-brain influx and decreased brain-to-blood efflux of 
A crossing the BBB lead to the A accumulation in brain. 
This also suggested the changed permeability of BBB and 
decreased A clearance of brain in AD patients (Deane et 
al., 2004; LaRue et al., 2004). LPS may play a role in A 
accumulation and AD progression. Intraperitoneal injections 
of LPS to mice alters the BBB transport of A protein 
through increasing blood-to-brain influx, decreasing 
brain-to-blood efflux and increasing neuronal A 
production (Jaeger et al., 2009). Other studies showed that 
intraperitoneal injections of LPS to mice could also lead to 
serious memory problems (Kahn et al., 2012; Lee et al., 
2008).  
Calprotectin is a kind of protein released from 
neutrophils and monocytes and elevated fecal calprotectin 
may serve as a marker of intestinal inflammation. There was 
a highly significant correlation between intestinal permea- 
bility and calprotectin concentration in gut lavage fluid 
(Berstad et al., 2000). Leblhuber et al. analyzed the fecal 
calprotectin concentration of 22 patients with AD and found 
that the patients presented with calprotectin concentrations 
outside normal (Leblhuber et al., 2015).  
Increased concentrations of plasma LPS and fecal 
calprotectin indicate a disturbed intestinal barrier function 
and increased intestinal inflammation and permeability in 
AD patients. These results further support that the gut and 
gut microbiota may participate in AD pathogenesis.  
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The influence of gut microbiota on neurochemical and 
metabolism and AD 
Gram-positive Lactobacillus and Bifidobacterium in the gut, 
such as Lactobacillus brevis and Bifidobacterium dentium, 
are able to produce -aminobutyric acid (GABA) by 
metabolizing glutamate (Barrett et al., 2012). GABA is the 
major inhibitory neurotransmitter in human CNS. 
Dysfunction of the GABAergic system may contribute to 
cognitive impairment (Lanctot et al., 2004). The increase of 
GABA in the gastrointestinal tract is correlated with the 
increase of GABA in CNS. Gut microbiota disruption, 
especially the reduction of Lactobacillus and 
Bifidobacterium, will influence the production of GABA in 
the gut and then lead to reduction of GABA in CNS. 
Postmortem study of AD patients found that the GABA 
levels were decreased in frontal, temporal and parietal 
cortex of AD patients (Lanctot et al., 2004; Solas et al., 
2015). 
Serotonin (5-hydroxytryptamine, 5-HT) is very important 
in regulating cognitive function. More than 95% of the 
5-HT are synthesized in the gut, and gut microbiota plays an 
important role in the synthesis of 5-HT. The content of 
5-HT in the blood of GF mice was about 60% lower than 
that of the SPF mice with a normal gut microbiota, and the 
concentration was significantly increased when the gut 
microbiota was reconstructed in GF mice (Yano et al., 
2015). Researchers analyzed the influence of gut microbiota 
on cerebral metabolism through assessing the cerebral 
metabolome of GF mice and Ex-GF mice which were 
colonized with fecal microbiota obtained from SPF mice 
(Matsumoto et al., 2013). The concentrations of 38 
metabolites were significantly altered between GF mice and 
Ex-GF mice, and about 10 of these metabolites were 
reported to be involved in brain function. The concentration 
of tryptophan (Trp), precursors of 5-HT, was lower in the 
cerebrum of GF mice than that of Ex-GF mice (Matsumoto 
et al., 2013). These indicate the changed 5-HT biosynthesis 
pathway in GF mice. Animal and human clinical trials have 
found that selective serotonin reuptake inhibitors (SSRIs) 
could reduce the A protein production in the brain, 
indicating that the increase extracellular 5-HT levels can 
effectively reduce A plaque formation and thereby reduce 
the risk of AD (Cirrito et al., 2011). These also indicate that 
the changed 5-HT biosynthesis caused by gut microbiota 
disturbance may affect the pathological process of AD. 
Glutamate is the main excitatory neurotransmitter in the 
human CNS, and N-methyl-D-aspartate glutamate receptor 
(NMDA) is one of the glutamate receptors of CNS. NMDA 
receptor plays important roles in neurodevelopment, 
participating in regulating neuronal survival, dendrites and 
axons development and synaptic plasticity. NMDA receptor 
also plays a key role in the formation of neuronal circuits. 
Evidences indicated that NMDA receptor is vital for 
learning and memory (Lakhan et al., 2013; Li and Tsien, 
2009). Researches show that there is also a certain 
relationship between gut microbiota and NMDA receptor 
expression. The mRNA expression of hippocampal NMDA 
receptor NR2B subunit is significantly decreased in GF 
mice (Neufeld et al., 2011). Disruption of gut microbiota by 
antibiotics treatment also significantly reduces the level of 
NMDA receptor in hippocampus (Wang et al., 2015).   
Brain derived neurotrophic factor (BDNF) is a protein 
synthesized in the brain and widely distributed in the CNS. 
BDNF displays its importance in neuronal survival, 
differentiation, growth and development in the process of 
CNS development. BDNF can also prevent neuronal 
damage and death, improve the pathological state of 
neurons and promote the regeneration and differentiation of 
damaged neurons. BDNF is essential for neurons of mature 
peripheral nervous system to maintain survival and normal 
physiological function. The expression of BDNF protein 
significantly decreased in GF mice, accompanied with 
changes of cognitive function (Gareau et al., 2011). Other 
studies also found the down-regulated mRNA expression of 
BDNF in hippocampus of GF mice (Clarke et al., 2013; 
Diaz Heijtz et al., 2011). Interestingly, mice deficient in 
BDNF have altered development of gastric vagal sensory 
innervation (Murphy and Fox, 2010). Investigation also 
found that the levels of BDNF in the brain and serum of AD 
patients were significantly decreased (Carlino et al., 2013). 
The above studies indicate that gut microbiota may affect 
host cognition by regulating the expression of BDNF and 
eventually induce AD.  
Cyanobacteria or blue-green algae in the gut microbiota 
may produce neurotoxin -N-methylamino-L-alanine 
(BMAA) which is considered to be related to development 
of AD (Banack et al., 2010; Brenner, 2013). Stress, anxiety, 
chronic intestinal inflammatory disease or malnutrition may 
further induce BMAA production and eventually lead to 
dysfunction of nervous system. BMAA is a neurotoxic 
amino acid which can be incorrectly insert into the 
polypeptide chains of brain proteins and then lead to protein 
misfolding, a hallmark characteristic of A plaque in AD 
patients (Mulligan and Chakrabartty, 2013). Recent research 
found that chronic dietary exposure to cyanobacterial toxin 
BMAA triggered NFT and A deposits in the brain and 
increased the risk of AD (Cox et al., 2016). Other 
cyanobacteria produced neurotoxins including saxitoxin 
and anatoxin- may further lead to neurological diseases, 
especially in the process of aging (Brenner, 2013). 
Therefore, an increase in the number of cyanobacteria in 
the gut may increase the risk of AD. 
Gut microbiota can also produce all kinds of vitamins 
necessary for brain health, including vitamin B12. Studies 
confirm that a lack of vitamin B12 is an important risk 
factor of dementia. Low levels of vitamin B12 in serum is 
associated with an increased risk of AD and MCI (Quadri et 
al., 2004). In the healthy elderly population, the levels of 
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vitamin B12 in serum are positively related to cognitive 
ability (Duthie et al., 2002). Although we can obtain 
vitamin B12 from diet, there are still a large amount of 
vitamin B12 synthesized by gut microbiota to meet our 
daily requirements. An American investigation shows that 
vitamin B12 deficiency affects 10%–15% of people over the 
age of 60 years (Pautas et al., 1999), and these may be due 
to the poor diet and medication use influence the 
composition of gut microbiota and subsequently result in 
lower vitamin B12 synthesis. 
The accumulation of A is one of the main pathological 
features of AD, and the A production and clearance in 
CNS is in dynamic equilibrium. A lot of bacteria and fungi 
can secret amyloid proteins, leading to increased contents of 
amyloid protein in CNS and the whole body, which 
subsequently break the dynamic equilibrium and result in 
A accumulation and higher AD risks (Hill and Lukiw, 
2015). 
Recently, researchers analyzed the urinary volatiles in 
mouse models of AD using gas chromatography/mass 
spectrometry (GC/MS), and uncovered some changed 
volatile metabolites (Kimball et al., 2016). These changes 
are not the production of new metabolites, but the 
alterations of concentration of the existing metabolites in 
urine, and these changes often occur before the pathological 
changes in brain. A large part of the ingredients in urine are 
originated from the metabolism of gut microbiota, and the 
changes of urine components also indicate the changes of 
gut microbiota (Evenepoel et al., 2009). The alterations of 
the urine metabolome in AD mice may be associated with 
the differences of gut microbiota. The changes occur before 
the brain pathological changes indicate the gut microbiota 
also changes before the brain pathological changes. The 
changes of gut microbiota could ultimately lead to 
pathological changes in the brain, and even the occurrence 
of AD.   
The research of metagenome, transcriptome, proteome 
and metabolome revealed the role of gut microbiota on 
health and disease. Everyone has a unique composition of 
gut microbiota. The individual differences of biochemical 
reaction may lead to individually different sensitivity to 
aging-related diseases, such as AD. 
INDIRECT EVIDENCE OF GUT MICROBIOTA 
AFFECT AD 
Hygiene hypothesis for AD 
The “hygiene hypothesis” that put forward in the 1980s 
points out the improved sanitation in early life is associated 
with lower exposure to microorganisms and lead to 
increased probability of allergic diseases in the future 
(Strachan, 1989). Exposure to microorganisms is vital for 
the development of immune system, and studies show that 
immune dysfunction is related to inadequate exposure to 
microorganisms (Rook, 2012). Certain aspects of modern 
life, such as abuse of antibiotics, use of food additives and 
preservatives, clean drinking water, improved sanitation, all 
result in lower and lower amount of microorganisms 
exposure, including some harmless microbes and parasites. 
T cells are important factors to regulate immune functions 
and T-cell system is the main affected system in hygiene 
hypothesis (Rook, 2009). Persistent low-level stimulation 
on immune system, such as exposure to these harmless 
microbes, can induce naive T cell to transform into 
regulatory T cells (Treg), rather than to Th1 and Th2 cells 
(Rook and Lowry, 2008). Th1 cells promote immune 
responses against intracellular pathogens, mainly involved 
in cellular immunity; and Th2 cells play important roles in 
immune responses against extracellular pathogens, mainly 
involved in humoral immunity (Schwarz et al., 2001). 
Persistent strong response of Th1 cells is associated with 
autoimmune diseases and excessive Th2 response is related 
to allergy. Treg is key regulatory factor of immune tolerance 
and dysfunction of Treg will cause autoimmune disorders. 
The lack of exposure to microorganisms in infancy leads to 
insufficient stimulation to immune system and insufficient 
Treg proliferation, and ultimately promotes the development 
of allergic disease, autoimmune disease and chronic 
inflammatory disease (Romagnani, 2004; Rook, 2007). 
Epidemiological investigation found that higher exposure to 
microorganisms was associated with lower risk of 
autoimmune diseases and allergy, and less exposure to 
benign infectious pathogens in early life was related to 
higher risk of autoimmune diseases and allergy (Cookson 
and Moffatt, 1997; Lynch et al., 1993; Vonmutius et al., 
1992). 
AD is also a systemic inflammatory disease and shows 
elevated Th1-mediated inflammation, which is similar to 
autoimmune diseases (D’Andrea, 2005; Pellicano et al., 
2012). The similarity between AD and autoimmune diseases 
in immunology suggests there are certain similarities in 
epidemiology. The hygiene hypothesis for AD predicts the 
occurrence of AD may be negatively correlated with 
microbial diversity and positively associated with 
environmental sanitation. Dysfunction of immune system 
induced by inadequate stimulation to immunity may result 
in increased risk of AD through T cells system. It is 
considered to be the key period to establish the immune 
system from pregnancy to childhood, but the Treg 
proliferation is throughout the whole life, showing the 
age-related increase of numbers and reaching to the peak in 
adolescent and about 60 years old (Faria et al., 2008; Gregg 
et al., 2005; Prescott, 2008). Therefore, not only the 
immune stimulation in early life, but also the whole life, 
will affect the onset of AD. Exposure to microorganisms 
during the whole life may be associated with the risk of AD. 
The Treg number of peripheral blood is increased in AD and 
MCI patients when comparing with healthy individuals, and 
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Treg induced immunosuppression in MCI patients is stronger 
than AD patients and healthy controls (Saresella et al., 
2010). This could also explain why those individuals with 
adequate Treg function may develop to MCI, while 
individuals with inadequate Treg function may develop to 
AD among AD susceptible populations. Also, those 
individuals with adequate Treg function may stay longer in 
MCI phase, while those with inadequate Treg function may 
develop to AD more rapidly in the progression of AD. This 
also suggests that the onset of AD may support the hygiene 
hypothesis. 
In 2013, Dr. Fox Molly and colleagues compared the 
relationship between the microbial environment and the 
incidence of AD in 192 countries (Fox et al., 2013). 
Countries with lower degree of sanitation have significant 
reduced incidence of AD. In countries with higher degree of 
sanitation, which have lower levels of parasites and less 
diversity of gut microbiota, the prevalence of AD is rising. 
The indexes to evaluate the sanitation in infancy include 
residence, farm living history, number of siblings, birth 
order, exposure to animals, parasite infestation, and so on. 
Studies demonstrated that farm living (von Mutius and 
Vercelli, 2010), more siblings (von Mutius et al., 1994), 
later birth order (Matricardi et al., 1998), more exposure to 
pets (Apter, 2003), exhibited lower prevalence of allergy 
and autoimmune diseases. In developing countries and rural 
environment, the microbial diversity is higher and the 
opportunity to exposure to microorganisms is more 
adequate. While in developed countries and urban 
environment, due to the improvement of environmental 
sanitation, the microbial diversity is lower and the 
opportunity to exposure to microorganisms is reduced. 
People living in developed countries have higher incidence 
of AD compared to developing countries and AD 
prevalence at age 80 is higher in North America and Europe 
than other countries (Ziegler-Graham et al., 2008). A 
meta-analysis indicates that incidence of AD in Latin 
America, China and India is lower than in Europe and lower 
in rural than urban in these areas (Llibre Rodriguez et al., 
2008). Among populations with the same ethnic 
backgrounds, living in low sanitation environment exhibits 
lower AD risk than high sanitation (Hendrie et al., 1995). 
The risk of AD changes with the environmental sanitation, 
the incidence of AD in immigrant population is between 
their home country and adopted country and migrating from 
a high to low sanitation country can reduce the risk of AD 
(Yamada et al., 2002). These all suggested that sanitation 
was positively associated with AD risk, supporting the 
hygiene hypothesis. Having more siblings is also considered 
to have higher immune stimulation in early life because 
they can obtain more microbes from contacting with each 
other. Children of later birth order have more opportunities 
to exposure to microorganisms than those of earlier birth 
order because they have longer time to play with siblings. 
Individuals with more siblings and later birth order have 
lower incidence of allergies (Jarvis et al., 1997; Matricardi 
et al., 1998), but there are still no reports about the number 
of siblings or birth order and incidence of AD. 
Microbial infection and AD 
More and more studies begin to pay great attention to the 
role of microbial infection in aging and AD. The majority of 
pathological changes in AD patients, including 
inflammation, brain atrophy, immune abnormalities, 
amyloid formation, changes of gene expression and 
cognitive impairment, are all considered to be associated 
with microbial infections (Bhattacharjee and Lukiw, 2013; 
Heintz and Mair, 2014; Huang et al., 2014; Mancuso et al., 
2014; Miklossy, 2011). Gut microbiota and host form the 
complex of mutualistic symbiosis in normal conditions and 
the symbiotic environment can effectively suppress the 
infection of potential pathogenic microorganisms. When the 
symbiotic environment is destroyed, numbers of potential 
pathogens will increase rapidly and eventually lead to the 
occurrence of diseases, including autoimmune disease, 
diabetes, metabolic syndrome, obesity, and stress induced 
mental illness, such as autism, schizophrenia and AD. 
Human CNS is threatened from a large number of 
exogenous and endogenous microorganisms and pathogens 
all the time, including bacteria, fungi, viruses, parasites, and 
so on. Almost all types of microbes are thought to be 
associated with AD, especially in the process of aging. 
Because innate immune and physiological barrier function 
are damaging with aging, and microbes and some 
neurotoxic substances are more easily to enter the CNS, 
resulting in inflammation and injuries (Tran and 
Greenwood-Van Meerveld, 2013).   
Infections of Chlamydophila pneumoniae, Helicobacter 
pylori, Toxoplasma gondii, Herpes simplex virus (HSV), 
Human immunodeficiency virus (HIV), Human 
cytomegalovirus (HCMV) and other common pathogens are 
all considered to be associated with the pathogenesis of AD 
(Balin et al., 1998; Borjabad and Volsky, 2012; Itzhaki and 
Wozniak, 2008; Kountouras et al., 2012; Lurain et al., 2013; 
Prandota, 2014). In a prospective cohort of healthy 
individuals, Katan et al. found a correlation between 
infectious burden and cognitive impairment assessed using 
the mini-mental state examination (MMSE) (Katan et al., 
2013). Strandberg et al. found that individuals with 
seropositive for some common viruses displayed cognitive 
impairment in home-dwelling elderly persons (Strandberg et 
al., 2003).  
C. pneumoniae is a gram-negative bacterium that can 
cause pneumonia. Early in 1998, scientists detected C. 
pneumoniae infection in postmortem brain of AD patients 
(Balin et al., 1998). In 2006, immunohistochemical analysis 
showed the C. pneumoniae infection in astrocytes, 
microglia and neurons of AD brain and the infected cells 
closed to SP and NFT in AD brain (Gerard et al., 2006). 
This suggests C. pneumoniae infection contributes to AD 
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pathology. A deposition is induced in mice brain following 
intranasal infection with C. pneumoniae isolated from an 
AD brain, suggesting the infection involved in the initiation 
of AD (Little et al., 2004). In in vitro experiment, C. 
pneumoniae infection induced the elevation of 
pro-inflammatory cytokines in culture supernatant of mice 
astrocyte, including MCP-1, IL-6, TNF- (Boelen et al., 
2007). The cell death was markedly increased when the 
neurons were putting into the culture supernatant of mice 
astrocyte infected with C. pneumoniae (Balin and Hudson, 
2014; Boelen et al., 2007). The results show that C. 
pneumoniae infection may stimulate pro-inflammatory 
response and promote the production of a series of 
cytokines and chemokines through activating microglia and 
astrocytes, and then lead to neurodegeneration and play an 
important role in neuroinflammation and even AD 
pathology.  
H. pylori a gram-negative bacterium attached to the 
gastric epithelial cells, and is considered to be the main 
cause of chronic gastritis and gastric ulcer and even gastric 
cancer. Recent case-control studies showed the correlation 
between H. pylori infection and AD. AD patients infected 
with H. pylori display lower scores in MMSE and more 
serious cognitive impairment (Roubaud-Baudron et al., 
2012). The eradication of H. pylori of AD patients can 
prolong AD survival, also potential suggesting that H. 
pylori infection may participate in the pathogenic process of 
AD (Kountouras et al., 2012). H. pylori infection may 
influence the pathophysiology of AD through releasing 
proinflammatory cytokines and inducing oxidative stress 
(Kountouras et al., 2007). 
T. gondii is an intracellular parasite, which can cause 
encephalitis and nervous system dysfunction by promoting 
chronic inflammation in the brain and CNS. Studies found 
that serum anti-T. gondii immunoglobulin G antibody levels 
significantly increased in AD patients, suggesting a link 
between AD and T. gondii infection (Prandota, 2014).  
HSV-1 is a neurotropic virus with high infection rates in 
populations. Once infection, HSV-1 will establish lifelong 
latency in trigeminal ganglia of peripheral nervous system. 
The virus will be activated in stress conditions. The immune 
function weakens with aging in elderly, and HSV-1 can 
easily enter the CNS to cause neurological diseases. HSV-1 
can cause herpes simplex encephalitis (HSE) and the 
pathological characteristic of affected regions of brain in 
HSE patients is very similar to AD patients (Ball, 1982). 
This indicates HSV-1 infection may participate in AD 
progression. Plenty of evidences show that HSV-1 may be a 
risk factor of AD. Epidemiology survey data show that 
HSV-1 DNA is detected in 90% of the amyloid plaques of 
AD patients (Wozniak et al., 2009b). The total content of 
Tau protein in the brain of AD patients is more than normal 
and displayed decreased normal Tau protein and increased 
abnormal phosphorylated Tau protein. HSV-1 infection can 
promote the Tau protein phosphorylation in brain (Wozniak 
et al., 2009a). A pro-inflammatory miRNA-146a is 
up-regulated in HSV-1 infected human primary brain cells 
as well as in the brain of AD patients (Lukiw et al., 2010). 
All of these show a close connection between HSV-1 
infection and AD. 
HIV is a lentivirus belonging to the family Retroviridae 
to infect human immune system, causing acquired 
immunodeficiency syndrome (AIDS). The virus destroys 
the host immunocompetence, making the body vulnerable to 
infections. HIV can damage the brain, spinal cord and 
peripheral nerve. HIV-associated neurocognitive disorder 
(HAND) has become a common manifestation of HIV 
infection, including AIDS dementia complex, 
HIV-associated encephalopathy, AIDS-associated cognitive 
decline (Borjabad and Volsky, 2012). Histopathological 
study found that HIV infected brain displayed brain atrophy 
and neuronal loss similar to AD patients (Widera et al., 
2014). Comparative analysis found that there are common 
mis-regulated genes in the brain of HAND and AD patients, 
involved in neuroimmune responses and synaptic 
transmission (Borjabad and Volsky, 2012). All of these 
show that HIV infection can promote the pathogenesis of 
AD. 
HCMV is also one of the important members of family 
Herpesviridae. HCMV infection in healthy individuals is 
often ignored, but it may threaten life once infecting 
immunecompromised, HIV infected or organ transplanted 
people. Researchers analyzed the serum, cerebrospinal fluid 
(CSF) and cryopreserved lymphocytes from AD patients to 
study the relationship between CMV infection and clinical 
and pathological hallmarks of AD (Lurain et al., 2013). 
NFT numbers of AD patients are positively associated with 
CMV antibody levels. The percentage of senescent T cells 
(CD4+ or CD8+CD28CD57+) is significantly higher in 
CMV-seropositive individuals compared to CMV-seroneg- 
ative individuals, which is related to the pathologic 
diagnosis of AD. These data suggest the correlation 
between CMV infection and the onset of AD. 
In addition, some periodontopathic spirochaete and 
hepatitis C virus (HCV) infection is also found to be 
associated with the onset of AD, significantly increasing the 
risk of AD (Chiu et al., 2014; Poole et al., 2013).  
Chronic fungal infection can also increase the risk of 
AD. Recent researches found yeast and fungal proteins in 
the peripheral blood of AD patients, including 1,3--glucan 
and fungal polysaccharides (Alonso et al., 2014a, b). Pisa et 
al. detect the postmortem brain tissues of 11 AD patients 
and 10 control individuals using specific antibodies against 
several fungi, and found fungal cell and hyphae in CNS of 
AD patients, but not in control individuals (Pisa et al., 
2015).  
Gut microbiota plays an important role in host defense, 
can effectively protect against exogenous pathogens 
infection, and GF animals are more vulnerable to infection 
(Clemente et al., 2012). It is easy to understand the 
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protective role of gut microbiota on intestinal pathogens 
infection. Epidemiological investigation indicates that 
Clostridium difficile colitis usually occurs after antibiotics 
therapy and suggests antibiotics induced gut microbiota 
disruption may promote the occurrence of infection (Crogan 
and Evans, 2007). Sekirov et al. found that antibiotics 
induced perturbations of the gut microbiota in C57BL/6 
mice predisposed the host to Salmonella enterica serovar 
Typhimurium infection, suggesting the importance of 
healthy gut microbiota in host resistance to the intestinal 
pathogens infections (Sekirov et al., 2008). Gut microbiota 
not only involved in gut immunity, but also recognized as 
an important modulator in systemic immunity, so it is not 
difficult to understand the protective role of gut microbiota 
on extraintestinal infections. Schuijt et al. depleted the gut 
microbiota in C57BL/6 mice and then intranasally infected 
with Streptococcus pneumoniae, and reflected increased 
bacterial dissemination, inflammation, organ damage and 
mortality compared with controls (Schuijt et al., 2016). 
FMT in these gut microbiota depleted mice alleviated the 
influence of S. pneumoniae infection (Schuijt et al., 2016). 
This study identifies the gut microbiota as a protective 
mediator during S. pneumoniae infection. Although, there 
are no direct evidences that gut microbiota plays protective 
roles in C. pneumoniae, HSV, HCMV infections, based on 
the above researches, we have reason to believe that the 
imbalance of gut microbiota can increase the host 
susceptibility to infections. So, disturbed gut microbiota 
may increase the chances of host infections by pathogens 
and promote the onset of AD, while healthy gut microbiota 
can prevent the infections and reduce the risk of AD.  
SOME COMMON DISEASES AND AD 
Irritable bowel syndrome (IBS) and inflammatory bowel 
disease (IBD) are two common gastrointestinal diseases. 
IBS is a common functional gastrointestinal disease related 
to changes of microbiota-gut-brain axis, usually manifested 
in the case of stress or enteric infection. IBD is usually 
characteristic of increased intestinal permeability, disrupted 
gut microbiota and inflammation. IBS and IBD patients are 
usually show a decline in cognitive ability, suggesting the 
potential relationship between gut and cognitive functions 
(Castaneda et al., 2013; Gomborone et al., 1993). 
Many cardiovascular risk factors, such as obesity, 
hypertension, diabetes and so on, are also associated with 
AD. Diabetes is a metabolic disease of insulin deficiency or 
insulin resistance, which has been proved to be associated 
with the changes in gut microbiota (Tilg and Moschen, 
2014). Diabetes is usually accompanied with a moderate 
injury in learning and memory. A study published in New 
England Journal of Medicine in 2013 reported that elevated 
blood glucose levels would increase the risk of cognitive 
impairment whether they are suffering from diabetes (Crane 
et al., 2013). The learning and memory ability will be 
improved in people suffering from diabetes as the effective 
control of blood glucose (Vanhanen et al., 1999). Probiotics 
(L. acidophilus, B. lactis and L. fermentum) in drinking 
water can not only significantly reduced fasting blood 
glucose levels, but also reverse the impairment of synaptic 
activity and cognitive function in diabetic rats (Davari et al., 
2013). Whether the gut microbiota alterations in diabetes 
participate in the regulation of cognitive functions of 
patients need to be further studied.  
Hepatic encephalopathy (HE) is also generally 
considered to be occurred under the background of gut 
microbiota induced intestinal permeability increases 
(Benjamin et al., 2013). There are strong correlations 
between some special bacteria (Alcaligeneceae, 
Porphyromonadaceae, and Enterobacteriaceae) and the 
onset of HE, declined cognitive function and inflammation 
(Bajaj et al., 2012). Rifaximin or lactulose can improve the 
cognitive functions and health-related quality of life in HE 
patients (Prasad et al., 2007; Sidhu et al., 2011). These 
studies suggest that cognitive impairment in HE patients 
may be caused by gut microbiota disruption, because 
rifaximin and lactulose directly or indirectly act on gut 
microbiota, inhibiting the growth of ammonia-producing 
bacteria and reducing ammonia production in the gut. They 
improve the cognitive impairment of HE patients by 
changing the gut microbiota and metabolites (Bajaj et al., 
2013).  
Parkinson’s disease (PD) is a common kind of CNS 
disease, and study found that gut microbiota composition 
was significantly altered in PD patients (Scheperjans et al., 
2015). The hallmark of PD is the formation of -synuclein 
enriched Lewy bodies. Holmqvist et al. found that 
-synuclein could spread from the gastrointestinal tract to 
the brain via the vagal nerve in rats, suggesting that PD 
might be originated from the gut (Holmqvist et al., 2014).  
At present, there are no research reports directly indicate 
the association between AD and gut microbiota. Based on 
the relationship between some intestinal disease (IBS, IBD) 
or extraintestinal disease (diabetes, HE) and cognitive 
impairment and gut microbiota as well as the correlation 
between the CNS disorders PD and gut microbiota, we 
speculate that other neurodegenerative diseases also 
probably begin in the gut and directly related to the 
disturbance of gut microbiota, including AD.  
CONCLUSIONS 
Gut microbiota regulates host brain functions and behavior 
via microbiota-gut-brain axis. GF animals,  antibiotics 
interference, probiotics intervention, pathogens infection, 
dietary habit, and so on, could not only affect the 
composition of gut microbiota and physiological function of 
gut, but also affect the host cognitive behavior and change 
the risk of AD. Thinking about the rapid increase of AD 
within the past decades, abuse of preservatives, variety of 
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additives in food processing could be considered as one of 
the most important reasons. Our dietary habit and lifestyle 
have been badly changed by excessive intake or over 
nutrition in daily life, which has been leading an unbalanced 
food consumption, then, causing gut microbiota collapse. 
Disturbance of gut microbiota may directly lead to 
increased intestinal permeability (leaky gut) and BBB 
permeability (leaky brain) and cause systemic and CNS 
inflammation, ultimately result in the occurrence of 
neurological disorders. The metabolites of gut microbiota 
and its influence on host neurochemical changes may also 
increase or decrease the risk of AD, such as GABA, 5-HT, 
BMAA, the biosynthesis of vitamin and the expression of 
NMDA receptor and BDNF, and so on. Pathogens infection, 
including C. pneumoniae, H. pylori, HSV, HIV, HCMV, 
will increase the risk of AD. At the same time, the onset of 
AD also supports the “hygiene hypothesis”. Most recently, a 
new published study reported that antibiotic-induced 
perturbations in gut microbial diversity influenced 
neuro-inflammation and decreased A plaque deposition in 
a murine model of AD (Minter et al., 2016). All of these 
results demonstrate the pathology of AD may be associated 
with disturbance of gut microbiota. At present, there are 
very few researches directly focused on gut microbiota and 
AD. In the future, we can analyze the structural differences 
of gut microbiota between AD patients and healthy 
individuals to find out some AD associated specific 
microbes, and then transplant these particular microbes or 
the fecal microbiota of AD patients into GF animals or gut 
microbiota depleted laboratory animals to observe whether 
they can induce AD related disease phenotype of 
pathological hallmarks. And finally, we can study the 
mechanisms how gut microbiota participate in regulating 
AD pathology. Meanwhile, ApoE is a susceptibility gene of 
AD, and HSV infection and high fat diet can increase the 
risk of AD, especially in ApoE 4 allele carriers (Itzhaki 
and Wozniak, 2008; Laitinen et al., 2006), suggesting the 
risk of AD may be affected by the interaction between gut 
microbiota and host genes. The host genes also influence 
the gut microbiota composition to some extent, which 
further induce diseases (Ley, 2015). Therefore, external 
environmental factors induced gut microbiota disturbance as 
well as the influence of host genes on gut microbiota may 
interact together to determine the disease susceptibility, 
including the risk of AD. The host genes are inherited from 
parents and difficult to change, whereas the gut microbiota 
can be modulated by dietary intervention or probiotics 
supplementation. Previous clinical preliminary investigation 
of several AD patients in our laboratory indicates that 
probiotics supplementation can effectively improve the 
cognitive ability of AD patients, and these results have yet 
to be further verified. Predictably, modulation of gut 
microbiota through personalized diet or beneficial 
microbiota intervention will probably become a new 
treatment for brain disorders including AD. 
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